<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03386513</url>
  </required_header>
  <id_info>
    <org_study_id>IMGN632-0801</org_study_id>
    <nct_id>NCT03386513</nct_id>
  </id_info>
  <brief_title>Study of IMGN632 in Patients With Relapse/Refractory AML, BPDCN, ALL, Other CD123+ Hem Malignancies</brief_title>
  <official_title>A Phase 1/2, Multi-center, Open-label Study of IMGN632 Monotherapy Administered Intravenously in Patients With CD123-positive Acute Myeloid Leukemia and Other CD123-positive Hematologic Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ImmunoGen, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Jazz Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>ImmunoGen, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, multi-center, Phase 1/2 study to determine the MTD and assess the
      safety, tolerability, PK, immunogenicity, and preliminary anti-leukemia activity of IMGN632
      when administered as monotherapy to patients with CD123+ disease.

      The study is currently enrolling eligible AML, BPDCN and ALL patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study comprises a dose escalation phase followed by a dose expansion phase to further
      characterize the safety profile and confirm the MTD. IMGN632 will be administered IV on Day 1
      of each cycle, with cycles repeating every 21 days. Treatment will continue for up to 2
      cycles (6 weeks) in the absence of disease progression (PD), treatment intolerance, or
      withdrawal of consent.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 2, 2018</start_date>
  <completion_date type="Anticipated">February 2021</completion_date>
  <primary_completion_date type="Anticipated">August 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD) and recommended Ph2 dose (RP2D)</measure>
    <time_frame>28 Days</time_frame>
    <description>To determine the maximum tolerated dose (MTD) and the recommended Phase 2 dose (RP2D) of IMGN632 when administered as a single agent</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Treatment emergent adverse events</measure>
    <time_frame>Up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR) (complete response [CR= CR+CRp+CRi]+partial remission [PR])</measure>
    <time_frame>Up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters: maximum plasma concentration (Cmax) of IMGN632</measure>
    <time_frame>Up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters: area under the time-concentration curve (AUC) of IMGN632</measure>
    <time_frame>Up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters: terminal half-life (t½) of IMGN632</measure>
    <time_frame>Up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity: Presence of Antibody-Drug Antibody (ADA)</measure>
    <time_frame>Up to 12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">212</enrollment>
  <condition>Acute Lymphocytic Leukaemia</condition>
  <condition>Blastic Plasmacytoid Dendritic Cell Neoplasm</condition>
  <condition>Myeloproliferative Neoplasm</condition>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>Escalation and Expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Escalation: IMGN632 will be administered by IV on two different schedules for patients with relapsed/refractory AML or BPDCN:
Schedule A: Day 1 of each cycle, with cycles repeating every 21 days
Schedule B: Days 1, 4 and 8 of each cycle, with cycles repeating every 21 days
Expansion: IMGN632 will be administered based on the recommended phase 2 dose (RP2D) and schedule as determined in the Escalation Phase, across five expansion cohorts, for patients with 1) relapsed, refractory OR selected untreated BPDCN; 2) relapsed AML; 3) relapsed or refractory ALL; 4) other relapsed or refractory CD123+ hematologic malignancies; 5) other relapsed or refractory AML.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IMGN632</intervention_name>
    <description>CD123-targeted ADC</description>
    <arm_group_label>Escalation and Expansion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Disease Characteristics:

               1. Confirmation of CD123 positivity by flow cytometry or IHC. Patients who received
                  prior CD123-targeting agents will be allowed as long as the blasts still have
                  detectable CD123 expression.

               2. Dose Escalation - Relapsed or refractory AML (excluding acute promyelocytic
                  leukemia) or BPDCN, based on World Health Organization Classification

               3. Dose Expansion

                    -  Cohort #1 - Patients with relapsed or refractory BPDCN OR patients with
                       untreated BPDCN who are inappropriate for available therapies. BPDCN
                       patients considered inappropriate for available therapies must be either ≥
                       75 years of age OR 18 to 74 years of age if the patient has at least one
                       comorbidity that the physician judges to be incompatible with intense and
                       available therapies, eg, pulmonary, cardiac, hepatic, vascular comorbidities
                       or is ineligible for available therapies eg, hypoalbuminemia (serum albumin
                       &lt; 3.2 mg/dL) as an exclusion for tagraxofusp (ELZONRIS).

                    -  Cohort #2 - Patients will have relapsed AML.

                    -  Cohort #3 - Patients will have relapsed or refractory ALL (including any
                       subtypes: B-cell, T-cell, Ph+ and Ph-)

                    -  Cohort #4 - Patients will have relapsed or refractory other hematologic
                       malignancies not included in the cohorts above (eg, high-risk/very high-risk
                       MDS, MPN, CMML, CML blast crisis). Other CD123+ malignancies may be
                       considered upon discussion with the Sponsor.

                    -  Cohort #5 - Patients will have relapsed or refractory (to non-intense
                       therapies) AML.

          2. Prior therapies:

               1. Patients in Dose Escalation and Dose Expansion Cohort #1, #3, and #4 may have
                  received up to four prior lines of therapy.

               2. Patients in Dose Expansion Cohort #2 with AML may have received up to two prior
                  lines of therapy.

               3. Patients in Dose Expansion Cohort #5 with AML may have received up to three prior
                  lines of therapy.

        Exclusion Criteria:

          1. Patients who, in the judgment of their treating physician, have appropriate standard
             of care therapies will be excluded

          2. Patients with active central nervous system (CNS) disease will be excluded.

          3. Patients with a history of venous occlusive disease of the liver

          4. Patients with a history of Grade 4 capillary leak syndrome, or non-cardiac Grade edema
             are ineligible, eg, related to SL-401 or other etiology

          5. Myocardial infarction within six months prior to enrollment or has New York Heart
             Association Class III or IV heart failure, uncontrolled angina, severe uncontrolled
             ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active
             conduction system abnormalities prior to study entry

          6. Patients who have received any anti-cancer therapy including chemotherapy,
             immunotherapy, radiotherapy, hormonal, biologic, or any investigational agents within
             14 days or five half-lives, whichever is greater (with exception of hydroxyurea),
             prior to drug administration on this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patrick Zweidler-McKay, MD</last_name>
    <role>Study Director</role>
    <affiliation>ImmunoGen, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ImmunoGen Clinical Trials</last_name>
    <phone>781-895-0115</phone>
    <email>medicalaffairs@immunogen.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center and Research Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Justo Gonzalez</last_name>
      <email>Justo.GonzalezFabian@moffitt.org</email>
    </contact>
    <contact_backup>
      <last_name>Sabrina Hasan</last_name>
      <email>Sabrina.hasan@moffitt.org</email>
    </contact_backup>
    <investigator>
      <last_name>Kendra Sweet, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ryan Osborn</last_name>
      <email>RyanD_Osborn@DFCI.HARVARD.EDU</email>
    </contact>
    <investigator>
      <last_name>Daniel Deangelo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie MacDavid</last_name>
      <email>Stephanie.MacDavid@RoswellPark.org</email>
    </contact>
    <contact_backup>
      <last_name>Angela Kader</last_name>
      <phone>716-845-4485</phone>
      <email>angela.kader@roswellpark.org</email>
    </contact_backup>
    <investigator>
      <last_name>Eunice Wang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke Cancer Institute</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rachel Stowe, BSN, RN</last_name>
      <phone>919-681-4769</phone>
      <email>rachel.stowe@duke.edu</email>
    </contact>
    <contact_backup>
      <last_name>Susan Jones, BSN, RN</last_name>
      <phone>919-681-4769</phone>
      <email>susan.jones@duke.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Harry Erba, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor Scott &amp; White University Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Jones</last_name>
      <phone>214-820-1970</phone>
      <email>Lisa.Jones2@BSWHealth.org</email>
    </contact>
    <investigator>
      <last_name>Moshe Y Levy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-7095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joie Alvarez</last_name>
      <phone>713-792-7321</phone>
      <email>JAlvarez1@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Hagop Kantarjian, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roland Walter, MD</last_name>
      <phone>206-667-5000</phone>
      <email>rwalter@fredhutch.org</email>
    </contact>
    <investigator>
      <last_name>Roland Walter, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Besancon, Hopital Jean Minjoz</name>
      <address>
        <city>Besançon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric Deconinck, MD</last_name>
      <phone>+33 (0)3 81 66 87 97</phone>
      <email>edeconinck@chu-besancon.fr</email>
    </contact>
    <investigator>
      <last_name>Eric Deconinck, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Instituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori</name>
      <address>
        <city>Meldola</city>
        <zip>47014</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Federica Frabetti</last_name>
      <phone>+39 0543 739290</phone>
      <email>federica.frabetti@irst.emr.it</email>
    </contact>
    <contact_backup>
      <last_name>Giovanni Martinelli, MD</last_name>
      <phone>+39 0543 739480</phone>
      <email>Giovanni.martinelli@irst.emr.it</email>
    </contact_backup>
    <investigator>
      <last_name>Giovanni Martinelli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Instituto Europeo di Oncologia</name>
      <address>
        <city>Milano</city>
        <zip>20141</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chiara Busacca</last_name>
      <phone>+39 02 57489 403</phone>
      <email>Chiara.Busacca@ieo.it</email>
    </contact>
    <contact_backup>
      <last_name>Maria Chiara Massaro</last_name>
      <phone>+39 02 57489 403</phone>
      <email>maria.massaro@ieo.it</email>
    </contact_backup>
    <investigator>
      <last_name>Corrado Tarella, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari I Politècnic La Fe</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pau Montsinos, MD</last_name>
      <phone>+34 961 245 876</phone>
      <email>montesinos_pau@gva.es</email>
    </contact>
    <contact_backup>
      <last_name>David Bossis</last_name>
      <phone>+34 961 244 864</phone>
      <email>pellicer_dav@gva.es</email>
    </contact_backup>
    <investigator>
      <last_name>Pau Montesinos, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>December 21, 2017</study_first_submitted>
  <study_first_submitted_qc>December 28, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 29, 2017</study_first_posted>
  <last_update_submitted>December 5, 2019</last_update_submitted>
  <last_update_submitted_qc>December 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 9, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Antibody Drug Conjugate</keyword>
  <keyword>Other Hematologic Malignancies</keyword>
  <keyword>Myeloproliferative Neoplasms</keyword>
  <keyword>CD123</keyword>
  <keyword>MDS</keyword>
  <keyword>Relapsed, Refractory</keyword>
  <keyword>Acute Lymphocytic Leukaemia</keyword>
  <keyword>Blastic Plasmacytoid Dendritic Cell Neoplasm</keyword>
  <keyword>Acute Myeloid Leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

